Digital ischemia and necrosis: A rarely described complication of gemcitabine in pancreatic adenocarcinoma

Eiichiro So  
Keio University
Zachary D Crees  
Washington University School of Medicine in St. Louis
Danielle Crites  
Washington University School of Medicine in St. Louis
Andrea Wang-Gillam  
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation
https://digitalcommons.wustl.edu/open_access_pubs/11510

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Digital Ischemia and Necrosis: A Rarely Described Complication of Gemcitabine in Pancreatic Adenocarcinoma

Eiichiro So,1 Zachary D. Crees,2,* Danielle Crites,3 and Andrea Wang-Gillam3

Abstract
Background: Gemcitabine, alone or in combination with other agents, has become an important part of the standard of care for treatment of both resectable and unresectable/advanced pancreatic adenocarcinoma. Gemcitabine is generally considered to have a favorable toxicity profile, with myelosuppression and hepatotoxicity as the most common adverse effects. There are just two prior published case reports of gemcitabine-associated digital toxicity in the treatment of pancreatic adenocarcinoma, and few case reports when considering all solid tumors.

Presentation: A 70-year-old female developed hand numbness and tingling while receiving nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma. There was initial concern for Raynaud’s or nab-paclitaxel-associated neuropathy, thus nab-paclitaxel was discontinued. However, her symptoms progressed to severe pain and her digits became dusky. An extensive evaluation revealed no alternative etiology except gemcitabine-associated digital ischemia (DI). The patient was treated with discontinuation of gemcitabine, and starting nitrates, opiates, calcium-channel blockers, and enoxaparin but eventually progressed to dry gangrene.

Conclusion: Here we report a case of gemcitabine-associated DI, along with a review of the literature. Although a rare complication, DI must be recognized and treated promptly to reduce the likelihood of serious and permanent morbidity.

Keywords: gemcitabine; digital ischemia; pancreatic adenocarcinoma; digital necrosis

Introduction
Gemcitabine as a single agent or in combination therapy is a mainstay treatment for pancreatic adenocarcinoma.1,2 Gemcitabine is generally well tolerated, with a favorable toxicity profile.1 There are case reports of gemcitabine-associated digital ischemia (DI), but there are only two prior case reports in the treatment of pancreatic adenocarcinoma.3–5 Here we present a case of gemcitabine-associated DI in a patient with pancreatic adenocarcinoma, along with a literature review.

Case Report
A 70-year-old female with metastatic pancreatic adenocarcinoma receiving gemcitabine and nab-paclitaxel presented to clinic with numbness and tingling in her bilateral hands. Owing to initial concern for nab-paclitaxel-associated neurotoxicity, nab-paclitaxel was discontinued while the patient was continued on gemcitabine (cumulative dose 4160 mg/m²). At 2-week follow-up, the patient reported progressive tenderness, coolness, and purple discoloration of her bilateral index fingers that was initially relieved with warm water immersion. Gemcitabine was promptly discontinued and the patient was admitted for further management. The patient had previously received FOLFOX and then FOLFIRI. She had a history of soleal deep vein thrombosis but no history of rheumatological, connective tissue or peripheral vascular disease. She was a 15-pack/
year smoker but quit 2 years previously. Her medications included diltiazem, pravastatin, and aspirin.

Upon admission, the patient’s vital signs were within normal limits. Examination revealed bilateral necrotic index fingers (Fig. 1). Basic laboratories revealed leukocytosis, mild anemia, and hypoalbuminemia. The prothrombin time/international normalized ratio, partial thromboplastin time, lupus anticoagulant, anticardiolipin antibody, cryoglobulin S, C3/C4, and extractable nuclear antigen testing were unremarkable. Antinuclear antibody was positive with 1:320 titer and speckled pattern. Echocardiogram showed no evidence of intracardiac thrombi. CT angiography revealed no evidence of systemic emboli. Arterial Doppler studies showed immeasurable digit/arm indices (Fig. 2). Given the negative evaluation for competing etiologies, gemcitabine-associated DI was diagnosed. The patient was managed with gemcitabine discontinuation, along with initiation of calcium-channel blockade, nitrates, and opiates. Therapeutic enoxaparin was also initiated, but was subsequently discontinued because of gastrointestinal bleed. Despite treatment, the patient’s symptoms progressed to dry gangrene of the bilateral index fingers.

FIG. 1. Images of fingers/hands. Red arrows, bilateral index fingers demonstrating cyanosis, digital ischemia, and necrosis. Box, remaining digits demonstrating cyanosis and distal erythema.

FIG. 2. Digit-arm indices. Digit-arm arterial Doppler tracings and indices demonstrating loss of arterial flow to the bilateral index fingers (second digit).
## Table 1. Reported Cases of Gemcitabine-Associated Digital Ischemia

<table>
<thead>
<tr>
<th>Case</th>
<th>Age (y/o)</th>
<th>Sex</th>
<th>Malignancy</th>
<th>Risk factors</th>
<th>Chemotherapy regimen (cumulative dose)</th>
<th>Affected area</th>
<th>Treatment for digital ischemia</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>So et al. (this article)</td>
<td>70</td>
<td>F</td>
<td>Pancreatic</td>
<td>Former tobacco</td>
<td>Gemcitabine (4160 mg/m²)</td>
<td>Bilateral second digits</td>
<td>Stopped gemcitabine, started calcium-channel blockade, nitrates, opiates, and enoxaparin</td>
<td>Progressed to dry gangrene of the bilateral second digits</td>
</tr>
<tr>
<td>Kuhar et al.</td>
<td>65</td>
<td>M</td>
<td>Pancreatic</td>
<td>Renal impairment</td>
<td>Gemcitabine (4000 mg/m²)</td>
<td>All digits of both hands</td>
<td>Stopped gemcitabine, started prolonged infusion of a prostacycline analogue, NSAIDs, and opioids</td>
<td>Symptoms resolved in all digits except one, which required amputation</td>
</tr>
<tr>
<td>Kuhar et al.</td>
<td>77</td>
<td>M</td>
<td>Bladder</td>
<td>Tobacco, thrombocytosis and peripheral vascular disease</td>
<td>Gemcitabine (4000 mg/m²) Cisplatin</td>
<td>Two digits of a right foot</td>
<td>Stopped gemcitabine, started prolonged infusion of a prostacycline analogue, percutaneous luminal angioplasty of right superficial femoralis artery</td>
<td>Complete resolution</td>
</tr>
<tr>
<td>Zaima et al.</td>
<td>69</td>
<td>M</td>
<td>Pancreatic</td>
<td>Systemic sclerosis, tobacco, and diabetes</td>
<td>Gemcitabine (7600 mg/m²)</td>
<td>Multiple fingers and toes</td>
<td>Stopped gemcitabine, started prostaglandins, vasodilators, antiplatelet drugs, antithrombin, bosentan hydrate, and systemic nerve block</td>
<td>Fixed gangrene not requiring amputation of affected digits</td>
</tr>
<tr>
<td>Holstein et al.</td>
<td>70</td>
<td>F</td>
<td>Urothelial</td>
<td>none</td>
<td>Gemcitabine (3000 mg/m²) Cisplatin or carboplatin</td>
<td>Left fourth, fifth digits and right third, fourth digits</td>
<td>Stopped gemcitabine, started bilateral brachial plexus blockade, intravenous prostacyclin analogue, fractionated heparin, oral corticosteroids, and aspirin</td>
<td>Partial clinical improvement, but with residual fixed gangrene</td>
</tr>
<tr>
<td>Vénat-Bouvet et al.</td>
<td>61</td>
<td>M</td>
<td>Urothelial</td>
<td>Tobacco</td>
<td>Gemcitabine (10,000 mg/m²)</td>
<td>Second, third digits of bilateral hands</td>
<td>Stopped gemcitabine, started intravenous prostaglandin-E2 analogue</td>
<td>Complete resolution</td>
</tr>
<tr>
<td>Clowse and Wigley</td>
<td>50</td>
<td>F</td>
<td>Lung</td>
<td>Systemic sclerosis</td>
<td>Cisplatin (unspecified dose)</td>
<td>Right second, fourth, fifth fingers and left third finger</td>
<td>Started calcium channel blocker, prednisolone, cephalaxin, gabapentin, and two stellate ganglion blocks</td>
<td>Fixed gangrene requiring amputation of affected digits</td>
</tr>
<tr>
<td>Staff et al.</td>
<td>57</td>
<td>F</td>
<td>Ovarian</td>
<td>Hypercholes-terolemia and carpal tunnel syndrome</td>
<td>Gemcitabine (unspecified dose) Cisplatin</td>
<td>Left second, third, and fourth digits</td>
<td>Started aspirin, calcium channel blocker, low-molecular weight heparin</td>
<td>Partial clinical improvement NOS</td>
</tr>
<tr>
<td>Yildiz et al.</td>
<td>59</td>
<td>M</td>
<td>Lung</td>
<td>Tobacco</td>
<td>Gemcitabine (5000 mg/m²)</td>
<td>Digits of both hands</td>
<td>Stopped gemcitabine, started vasodilator agents, low-molecular weight heparin and aspirin</td>
<td>Partial clinical improvement, NOS</td>
</tr>
<tr>
<td>Banach and Williams</td>
<td>59</td>
<td>M</td>
<td>Lung</td>
<td>Diabetes</td>
<td>Gemcitabine (unspecified dose)</td>
<td>Right fourth digit, and left first, second digits</td>
<td>Stopped gemcitabine, started intermittent corticosteroids</td>
<td>Fixed gangrene</td>
</tr>
</tbody>
</table>

NOS, not otherwise specified; NSAID, non-steroidal anti-inflammatory drugs.
Discussion

Gemcitabine has been associated with thrombotic vascular complications affecting various organ systems. However, DI is a rare adverse effect of gemcitabine likely caused by drug-related microvascular endothelial damage and a relative hypercoagulable state, with only case reports to aid clinicians in identifying risk factors, recognizing signs/symptoms, and guiding management decisions. A PubMed search using “digital ischemia/necrosis” and “gemcitabine,” selecting English language articles and also using relevant cases from those articles’ references revealed nine cases of gemcitabine-associated DI (Table 1), with only two cases occurring in pancreatic adenocarcinoma. Risk factors included tobacco use, diabetes, peripheral vascular disease, systemic sclerosis, combination chemotherapy, and cumulative gemcitabine dose >10,000 mg/m². Two cases reported favorable outcomes. Kuhar et al. reported using infusion of a prostacycline analogue, NSAIDs, and opioids. Vénat-Bouvet et al. reported intra- venous prostaglandin-E2 analogue alone. In each case, gemcitabine was withdrawn.

In this case, there was no underlying disease. Prior smoking was the only risk factor. The cumulative gemcitabine dose of 4160 mg/m² was lower than previous reports. Given the lack of risk factors and initial suspicion for competing etiologies, gemcitabine was not immediately discontinued. Despite eventual discontinuation of gemcitabine and initiation of vasodilator therapy, the patient suffered irreversible digital necrosis. Therefore, based on variability in risk factors and cumulative dose exposure, clinicians should maintain a high degree of suspicion for gemcitabine-associated DI.

Conclusion

DI is a rare side effect of gemcitabine, which may be attributable to endothelial damage and a hypercoagulable state. There is variability in risk factors, presenting signs/symptoms, and treatment response, creating a diagnostic and treatment dilemma for clinicians. Withdrawing gemcitabine and initiation of prostaglandins and/or alternative vasodilators may be an effective treatment modality.

Author Disclosure Statement

Dr. Andrea Wang-Gillam serves on the advisory boards for Newlink, Pfizer, and Merrimack. The remaining authors have no relevant conflicts of interest or financial disclosures.

References


Abbreviations Used

CT = computed tomography
DI = digital ischemia,
NSAIDs = non-steroidal anti-inflammatory drugs

Publish in Journal of Pancreatic Cancer

- Immediate, unrestricted online access
- Rigorous peer review
- Compliance with open access mandates
- Authors retain copyright
- Highly indexed
- Targeted email marketing